142 related articles for article (PubMed ID: 9195099)
1. Asymptomatic hepatitis in persons who received alternative preventive therapy with pyrazinamide and ofloxacin.
Ridzon R; Meador J; Maxwell R; Higgins K; Weismuller P; Onorato IM
Clin Infect Dis; 1997 Jun; 24(6):1264-5. PubMed ID: 9195099
[No Abstract] [Full Text] [Related]
2. Recurrent Drug-Induced Hepatitis in Tuberculosis-Comparison of Two Drug Regimens.
Shamaei M; Mirsaeidi M; Baghaei P; Mosaei H; Marjani M; Tabarsi P
Am J Ther; 2017; 24(2):e144-e149. PubMed ID: 26057141
[TBL] [Abstract][Full Text] [Related]
3. Safety of an ofloxacin-based antitubercular regimen for the treatment of tuberculosis in patients with underlying chronic liver disease: a preliminary report.
Saigal S; Agarwal SR; Nandeesh HP; Sarin SK
J Gastroenterol Hepatol; 2001 Sep; 16(9):1028-32. PubMed ID: 11595068
[TBL] [Abstract][Full Text] [Related]
4. Pyrazinamide-induced granulomatous hepatitis.
Knobel B; Buyanowsky G; Dan M; Zaidel L
J Clin Gastroenterol; 1997 Jun; 24(4):264-6. PubMed ID: 9252856
[TBL] [Abstract][Full Text] [Related]
5. [Liver toxicity of aetina and pyracinamide and their control by determination of LAP activity in blood serum].
Matzel W; Lindemann I
Z Erkr Atmungsorgane Folia Bronchol; 1969; 131(1):87-98. PubMed ID: 5197904
[No Abstract] [Full Text] [Related]
6. Rifampin plus pyrazinamide-induced hepatitis requiring hospitalization in a 30-y-old male with latent tuberculosis.
Potolidis E; Mantadakis E; Zeniodi MH; Samonis G
Scand J Infect Dis; 2005; 37(2):155-7. PubMed ID: 15773037
[TBL] [Abstract][Full Text] [Related]
7. [Comparison of drug-induced hepatitis occurring in elderly and younger patients during anti-tuberculosis treatment with a regimen including pyrazinamide].
Miyazawa N; Horita N; Tomaru K; Tsukahara T; Takahashi R; Sasaki M; Ishigatsubo Y
Kekkaku; 2013 Mar; 88(3):297-300. PubMed ID: 23672170
[TBL] [Abstract][Full Text] [Related]
8. From the Centers for Disease Control and Prevention. Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection--New York and Georgia, 2000.
JAMA; 2001 May 23-30; 285(20):2572-3. PubMed ID: 11396466
[No Abstract] [Full Text] [Related]
9. Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection--New York and Georgia, 2000.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2001 Apr; 50(15):289-91. PubMed ID: 11330495
[TBL] [Abstract][Full Text] [Related]
10. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy.
Lee BH; Koh WJ; Choi MS; Suh GY; Chung MP; Kim H; Kwon OJ
Chest; 2005 Apr; 127(4):1304-11. PubMed ID: 15821209
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the hepatotoxic effect of antituberculous drugs in tuberculosis patients abusing alcohol.
Grymiński J; Lyczewska J; Styszewska H; Walczak J
Pol Med J; 1970; 9(3):635-44. PubMed ID: 5452841
[No Abstract] [Full Text] [Related]
12. [Liver injury under tuberculostatic treatment].
Fattinger K; Braunschweig S; Reichen J; Meier-Abt PJ; Krähenbühl S
Praxis (Bern 1994); 1997 Apr; 86(15):626-9. PubMed ID: 9213916
[TBL] [Abstract][Full Text] [Related]
13. From the Centers for Disease Control and Prevention. Update: Fatal and severe liver injuries associated with Rifampin and Pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations--United States, 2001.
JAMA; 2001 Sep; 286(12):1445-6. PubMed ID: 11596606
[No Abstract] [Full Text] [Related]
14. Hepatotoxicity of tuberculosis chemotherapy under general programme conditions in Singapore.
Teleman MD; Chee CB; Earnest A; Wang YT
Int J Tuberc Lung Dis; 2002 Aug; 6(8):699-705. PubMed ID: 12150482
[TBL] [Abstract][Full Text] [Related]
15. Hepatotoxicity after a short course of low-dose pyrazinamide.
al Sarraf KA; Michielsen PP; Hauben EI; Lefebure A; Ramon AM; Van Marck EA; Pelckmans PA
Acta Gastroenterol Belg; 1996; 59(4):251-3. PubMed ID: 9085628
[TBL] [Abstract][Full Text] [Related]
16. Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis.
Papastavros T; Dolovich LR; Holbrook A; Whitehead L; Loeb M
CMAJ; 2002 Jul; 167(2):131-6. PubMed ID: 12160118
[TBL] [Abstract][Full Text] [Related]
17. National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection.
McElroy PD; Ijaz K; Lambert LA; Jereb JA; Iademarco MF; Castro KG; Navin TR
Clin Infect Dis; 2005 Oct; 41(8):1125-33. PubMed ID: 16163632
[TBL] [Abstract][Full Text] [Related]
18. Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2002 Nov; 51(44):998-9. PubMed ID: 12455909
[TBL] [Abstract][Full Text] [Related]
19. [DRUG-INDUCED LIVER INJURY AND PYRAZINAMIDE USE].
Horita N; Miyazawa N
Kekkaku; 2015 Mar; 90(3):401-5. PubMed ID: 26477109
[TBL] [Abstract][Full Text] [Related]
20. [Hepatitis of prolonged development induced by various tuberculostatic drugs].
Brincourt J; Teyssier L
Rev Tuberc Pneumol (Paris); 1968; 32(6):831-8. PubMed ID: 5743631
[No Abstract] [Full Text] [Related]
[Next] [New Search]
